DB:IBT

Stock Analysis Report

Executive Summary

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally.

Risk Analysis

Earnings have declined by -3.94% per year over past 5 years

Does not have a meaningful market cap (€4M)

Highly volatile share price over past 3 months

Does not have meaningful revenue (CA$4M)



Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has IBEX Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IBT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.5%

IBT

0.4%

DE Biotechs

0.2%

DE Market


1 Year Return

-20.8%

IBT

9.0%

DE Biotechs

14.4%

DE Market

Return vs Industry: IBT underperformed the German Biotechs industry which returned 9% over the past year.

Return vs Market: IBT underperformed the German Market which returned 14.4% over the past year.


Shareholder returns

IBTIndustryMarket
7 Day0.5%0.4%0.2%
30 Day13.1%-2.1%0.9%
90 Day36.6%8.0%4.6%
1 Year-20.8%-20.8%9.2%9.0%17.9%14.4%
3 Year-9.2%-9.2%45.5%43.9%15.7%5.6%
5 Year94.1%94.1%12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is IBEX Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is IBEX Technologies undervalued compared to its fair value and its price relative to the market?

0.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IBT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IBT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IBT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IBT is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IBT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IBT is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is IBEX Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

34.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IBEX Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has IBEX Technologies performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IBT is currently unprofitable.

Growing Profit Margin: IBT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IBT is unprofitable, and losses have increased over the past 5 years at a rate of -3.9% per year.

Accelerating Growth: Unable to compare IBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: IBT has a negative Return on Equity (-14.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is IBEX Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: IBT's short term assets (CA$3.6M) exceed its short term liabilities (CA$823.9K).

Long Term Liabilities: IBT's short term assets (CA$3.6M) exceed its long term liabilities (CA$1.4M).


Debt to Equity History and Analysis

Debt Level: IBT's debt to equity ratio (14.7%) is considered satisfactory.

Reducing Debt: IBT's debt to equity ratio has reduced from 26.6% to 14.7% over the past 5 years.


Balance Sheet

Inventory Level: IBT has a high level of physical assets or inventory.

Debt Coverage by Assets: IBT's debt is covered by short term assets (assets are 3.7x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBT has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: IBT has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is IBEX Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IBT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IBT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Paul Baehr (76yo)

CA$246,342

Compensation

Mr. Paul Baehr has been the Chairman and Chief Executive Officer of IBEX Technologies, Inc. since October 1995 and serves as its President. Mr. Baehr serves as the President of Bio-Research Products, Inc.  ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD186.27K) is below average for companies of similar size in the German market ($USD412.57K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Paul Baehr
President0yrsCA$246.34k9.92% CA$257.5k
Robert DeLuccia
Lead Director0yrsCA$27.63k0.27% CA$7.1k
Danilo Netto
Independent Director12.3yrsCA$25.31k0.087% CA$2.3k
Bruce Connop
Independent Director2.3yrsCA$23.30kno data
Joseph Zimmermann
Independent Director2.3yrsCA$20.97kno data

2.3yrs

Average Tenure

73yo

Average Age

Experienced Board: IBT's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IBEX Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IBEX Technologies Inc.
  • Ticker: IBT
  • Exchange: DB
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.716m
  • Listing Market Cap: CA$2.596m
  • Shares outstanding: 24.77m
  • Website: https://www.ibex.ca

Location

  • IBEX Technologies Inc.
  • 5485 Paré Street
  • Suite 100
  • Montreal
  • Quebec
  • H4P 1P7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IBTTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 1996
IBTDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 1996
IBXN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 1996

Biography

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. The company was founded in 1986 and is based in Montreal, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 20:58
End of Day Share Price2020/02/20 00:00
Earnings2019/10/31
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.